证券代码：300519 证券简称：新光药业 公告编号：2024-019 浙江新光药业股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决提案的情况； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开情况 1、浙江新光药业股份有限公司（以下简称"公司"）2023 年度股东大会会 议通知已于 2024 年 4 月 22 日以公告形式发出，本次会议采用现场投票和网络 投票相结合的方式召开。公司于 2024 年 5 月 14 日发布了《关于召开 2023 年度 股东大会的提示性公告》（公告编号 2024-018），具体内容详见公司于中国证 监会指定信息披露网站发布的公告。 2、股权登记日：2024 年 5 月 10 日（星期五） 3、会议召开的日期和时间 （1）现场会议召开时间：2024 年 5 月 17 日（星期五）下午 14:00。 （2）网络投票时间：2024 年 5 月 17 日。其中，通过深圳证券交 ...

Financial Performance - The company's revenue for Q1 2024 was ¥100,545,259.30, representing an increase of 8.94% compared to ¥92,296,717.31 in the same period last year[5] - Net profit attributable to shareholders decreased by 25.01% to ¥22,830,341.36 from ¥30,445,257.47 year-on-year[5] - Total operating revenue for Q1 2024 reached ¥100,545,259.30, an increase of 8.6% compared to ¥92,296,717.31 in the same period last year[22] - Net profit for Q1 2024 was ¥22,830,341.36, a decrease of 25.1% from ¥30,445,257.47 in Q1 2023[24] - The total comprehensive income for Q1 2024 was ¥22,423,099.18, down from ¥30,579,174.49 in Q1 2023[24] Cash Flow - The net cash flow from operating activities increased by 38.69% to ¥38,871,503.24, up from ¥28,027,614.00 in the previous year[5] - Cash flow from operating activities was ¥104,202,561.78, compared to ¥107,173,830.98 in the previous period[26] - The net cash flow from operating activities for Q1 2024 was CNY 38,871,503.24, an increase of 38.5% compared to CNY 28,027,614.00 in Q1 2023[27] - The net increase in cash and cash equivalents was ¥51,898,027.02, a significant rise of 2628.88% from ¥1,901,807.18 in the same period last year[12] - The ending balance of cash and cash equivalents as of the end of Q1 2024 was CNY 595,843,819.92, down from CNY 623,931,587.44 at the end of Q1 2023[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥944,717,593.83, a 1.54% increase from ¥930,405,790.36 at the end of the previous year[5] - The total liability of the company was ¥78,173,726.46, a decrease from ¥86,285,022.17 year-on-year[23] - The total assets of the company amount to ¥944.72 million, compared to ¥930.41 million at the beginning of the period[19] - The company's inventory decreased to ¥50.34 million from ¥71.42 million, reflecting a reduction of approximately 29.5%[19] - The total liabilities include accounts payable of ¥60.82 million, down from ¥63.88 million[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,742[13] - The largest shareholder, Wang Yuejun, holds 38.25% of the shares, totaling 61,200,000 shares[13] - The total number of shares held by the top ten shareholders is significant, with the top two shareholders holding a combined 55.89%[13] - The company has no preferred shareholders or related party transactions among the top shareholders[14][15] - The company has not reported any changes in the number of restricted shares during the period[16] Operating Costs and Expenses - The company experienced a 39.32% increase in operating costs, amounting to ¥62,812,898.25, primarily due to rising raw material prices[10] - Total operating costs amounted to ¥76,153,559.49, up 31.4% from ¥57,913,730.09 in Q1 2023[23] - Research and development expenses for Q1 2024 were ¥3,945,710.79, an increase from ¥3,581,334.49 in Q1 2023[23] - The cash paid for purchasing goods and services was CNY 34,469,387.44, which is an increase from CNY 32,692,801.45 in the same quarter last year[27] - The cash paid for taxes in Q1 2024 was CNY 13,214,297.95, a decrease of 48.9% compared to CNY 25,879,261.11 in Q1 2023[27] Investment Income - Investment income increased by 109.15% to ¥1,095,815.46, compared to ¥523,933.82 in the previous year[10] - The company recorded a financial income of ¥1,892,311.55, up from ¥1,291,891.86 in the same period last year[23] - Cash inflow from investment activities totaled CNY 106,261,564.38, up from CNY 95,575,369.86 in the same period last year, representing an increase of 11.7%[27] - The net cash flow from investment activities was CNY 13,026,523.78, a significant recovery from a negative cash flow of CNY -26,125,806.82 in Q1 2023[27] - The total cash outflow from investment activities was CNY 93,235,040.60, a decrease of 23.4% from CNY 121,701,176.68 in the previous year[27] Company Strategy - The company is focused on maintaining a stable financial position while exploring potential market expansions and new product developments[14]

Financial Performance - The company's operating revenue for 2022 was CNY 351,488,810.60, representing a 9.54% increase compared to CNY 320,876,074.74 in 2021[18]. - The net profit attributable to shareholders for 2022 was CNY 108,821,010.06, a decrease of 4.78% from CNY 114,280,359.13 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 104,960,678.02, down 3.69% from CNY 108,982,378.55 in 2021[18]. - The net cash flow from operating activities was CNY 126,429,397.43, which is a decline of 11.19% compared to CNY 142,355,309.64 in 2021[18]. - The total assets at the end of 2022 amounted to CNY 957,759,191.66, reflecting a 2.72% increase from CNY 932,403,805.04 at the end of 2021[18]. - The net assets attributable to shareholders increased by 1.50% to CNY 858,894,551.23 from CNY 846,217,071.35 in the previous year[18]. - The basic earnings per share for 2022 were CNY 0.68, down 4.23% from CNY 0.71 in 2021[18]. - The weighted average return on net assets was 12.88%, a decrease of 0.92% from 13.80% in the previous year[18]. - The company's gross profit margin was 51.85%, with operating costs rising by 19.07% to CNY 169.23 million[56]. - The company reported a decrease in net cash flow from operating activities by CNY 12.96 million, down 11.19% year-on-year[44]. Dividend Policy - The company plans to distribute a cash dividend of CNY 5.00 per 10 shares, totaling CNY 80,000,000 based on 160,000,000 shares[4]. - The cash dividend distribution policy requires a minimum of 20% of the distributable profit to be allocated as cash dividends during the growth phase with significant capital expenditure[150]. - The total distributable profit for the year 2022 is RMB 427,086,565.84[150]. - The company maintains a consistent and stable profit distribution policy, ensuring that cash dividend information is disclosed accurately[148]. - There were no adjustments or changes to the cash dividend policy during the reporting period[149]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing industry, which is experiencing growth due to factors such as an aging population and increased health awareness[28]. - The company anticipates that the demand for pharmaceutical products will continue to grow due to ongoing healthcare reforms and an increasing elderly population[30]. - The company is actively working to expand its market presence outside of Zhejiang province, where over 70% of its revenue has been generated in recent years[102]. - The company aims to strengthen marketing network construction and actively expand sales markets outside the province to increase market coverage and share[171]. - The company recognizes the risk of policy changes in the pharmaceutical industry, which may impact sales regions and pricing, and plans to adapt its marketing strategies accordingly[101]. Research and Development - The company has established a high-tech research and development center and collaborates with several universities for product innovation, holding 10 core independent intellectual property rights[40]. - R&D expenses totaled CNY 15.55 million, accounting for 4.42% of total revenue, focusing on product innovation and process improvement[49]. - The company has ongoing projects aimed at converting prescription drugs to OTC products, which are currently under technical review[64]. - The company has developed a sugar-free version of Huangqi Shengmai Drink to cater to the growing number of diabetes patients, indicating a proactive approach to market demands[36]. - The company intends to accelerate the construction of its "Modern Chinese Medicine R&D Center" and deepen cooperation with research institutions to expedite new product development and technology application[97]. Risk Management - The company acknowledges potential risks including industry policy changes and fluctuations in raw material prices, which may impact future performance[3]. - The company will implement measures to manage the risks associated with fluctuations in raw material prices, which could adversely affect profitability[103]. - The company faces risks related to the concentration of its product structure, with three main products significantly influencing revenue and profitability[102]. Governance and Compliance - The company has established a complete and independent financial management system, with dedicated accounting personnel and independent decision-making capabilities[115]. - The company adheres to legal and regulatory requirements in its governance structure, with no significant discrepancies identified[112]. - The company has a robust internal audit system to oversee financial reporting and risk management[111]. - The company has maintained compliance with regulatory requirements, with no penalties reported for board members in the last three years[126]. - The company has not encountered any significant internal control deficiencies during the reporting period[154]. Social Responsibility and Environmental Compliance - The company donated 1 million yuan to the Shenzhou Charity Association to support education, healthcare, and assistance programs during the reporting period[163]. - The company maintained compliance with environmental standards, with COD emissions at 1.26 tons and ammonia nitrogen emissions at 0.011 tons, both within permitted limits[159]. - The company has implemented a complete environmental self-monitoring plan and has passed ISO14001 environmental management system certification[160]. - The company has established a wastewater treatment facility that operates in accordance with national standards, ensuring no exceedance of discharge limits[160]. Future Outlook - The company aims for a revenue growth target of 0-10% for 2023 compared to the previous year[99]. - The company plans to enhance its marketing network, focusing on both domestic and external markets to cultivate new growth points for its leading products[96]. - The company is exploring partnerships with international firms to enhance its global footprint and increase export sales by 25% in the coming year[195]. - Future guidance suggests a revenue growth target of 30% for 2023, driven by new product launches and market expansion[196].

Financial Performance - Total revenue for 2023 was ¥270,399,837.67, a decrease of 23.07% compared to ¥351,488,810.60 in 2022[17]. - Net profit attributable to shareholders was ¥64,356,480.65, down 40.86% from ¥108,821,010.06 in the previous year[17]. - Basic earnings per share decreased to ¥0.40, a decline of 41.18% from ¥0.68 in 2022[17]. - Operating cash flow net amount was ¥53,290,425.47, representing a 57.85% decrease from ¥126,429,397.43 in 2022[17]. - Total assets at the end of 2023 were ¥930,405,790.36, down 2.86% from ¥957,759,191.66 at the end of 2022[17]. - The company reported a weighted average return on equity of 7.62%, down from 12.88% in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥60,123,577.68, a decrease of 42.72% from ¥104,960,678.02 in 2022[17]. - The company’s net assets attributable to shareholders decreased by 1.72% to ¥844,120,768.19 at the end of 2023[17]. - The gross profit margin for the pharmaceutical manufacturing industry was 41.27%, down by 10.58% from the previous year[46]. - The company’s main products contributed to revenue as follows: Huangqi Shengmai Drink accounted for 76.09%, Shenjindan Capsules 8.48%, and Western Ginseng Oral Liquid 12.43%[38]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of ¥4.00 per 10 shares, totaling approximately ¥64,000,000 based on 160,000,000 shares[3]. - The total distributable profit for the year is ¥404,909,630.62, indicating a strong profitability position[134]. - The cash dividend policy has not been adjusted or changed during the reporting period, ensuring consistency with the company's charter and dividend management guidelines[134]. - The company plans to distribute at least 20% of its distributable profits as cash dividends, with a minimum of 15% if there are no major capital expenditures[130]. - The cash dividend amount is based on a share capital base of 160,000,000 shares, ensuring clarity in the distribution process[137]. Research and Development - The company invested CNY 151.34 million in R&D, which is 5.60% of total revenue, focusing on new product development and process optimization[40]. - The company has filed for two invention patents and published two journal articles during the reporting period, reflecting its commitment to innovation and research[41]. - The company has established a provincial-level high-tech research and development center and collaborates with several universities for product innovation, holding 11 core independent intellectual property rights[34]. - Research and development expenses were CNY 15,134,245.96, a slight decrease of 2.67% compared to the previous year[54]. - The company is conducting clinical trials for the slow support granules to evaluate their effectiveness in treating COVID-19 recovery symptoms[56]. Market and Industry Trends - The pharmaceutical manufacturing industry is experiencing growth driven by an aging population, with 297 million people aged 60 and above in China as of December 2023, representing 21.1% of the total population[27]. - The Chinese traditional medicine market size reached CNY 481.80 billion in 2023, with an expected growth to CNY 510.20 billion in 2024, indicating a favorable market environment for the company[37]. - The government has introduced policies to support the development of traditional Chinese medicine, aiming to enhance its role in public health and healthcare systems[28][29]. - The pharmaceutical industry is experiencing stable growth due to factors such as rising income levels, increased medical insurance coverage, and an aging population, providing favorable conditions for the company's business development[33]. Risk Management - The company will actively monitor potential risks and take measures to achieve its operational goals for 2024[3]. - The company faces risks from industry policy changes, including stricter regulations on drug production and sales, which may impact its operations[85]. - The company is addressing the risk of product structure concentration, as its main products significantly influence revenue and profitability[85]. - The company is implementing measures to manage risks related to raw material price fluctuations, which could adversely affect profitability[86]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[92]. - The supervisory board held 5 meetings during the reporting period, reviewing 15 proposals, ensuring effective supervision of the company's financial and managerial compliance[92]. - The company emphasizes investor relations management, utilizing multiple channels for communication, including a dedicated investor hotline and online platforms[94]. - The company has established a complete and independent financial institution, ensuring independent accounting and financial decision-making[98]. - The company has maintained compliance with regulatory requirements, with no penalties reported for board members in the last three years[109]. Environmental Responsibility - The company has passed clean production audits and ISO14001 environmental management system certification, ensuring effective environmental management practices[147]. - The company has established a complete environmental self-monitoring plan with dedicated personnel and professional monitoring equipment to ensure compliance with discharge standards[148]. - The company has implemented a wastewater treatment station that adheres to the national "Comprehensive Wastewater Discharge Standards" level three (GB8978-1996) with actual discharge concentrations and volumes of COD and ammonia nitrogen within the approved standard limits[147]. - In 2023, the total COD discharge was 1.21 tons, while the permitted total discharge was 8.48 tons, indicating no exceedance of discharge standards[146]. Employee Management - The total number of employees at the end of the reporting period is 315, with 192 in production, 45 in sales, 45 in technical roles, and 11 in finance[124]. - The company has established a comprehensive training system to enhance employee skills and knowledge, including various training categories and evaluation mechanisms[127]. - The company has a differentiated compensation policy based on department, position, and job nature, linking employee remuneration closely with performance and company results[126]. - The company has a total of 86 employees with a bachelor's degree or higher, representing approximately 27% of the workforce[125]. Future Outlook - The company aims for a revenue growth target of 0-10% for 2024 compared to the previous year[84]. - The company plans to strengthen its marketing network and expand into out-of-province markets to cultivate new growth points for its leading products[82]. - The company is focused on expanding its market presence and developing new products, although specific figures on new product launches were not disclosed[103]. - Future outlook indicates a commitment to research and development, aiming to enhance product offerings and improve market competitiveness[104].

Financial Performance - Total revenue for 2023 was ¥270,399,837.67, a decrease of 23.07% compared to ¥351,488,810.60 in 2022[17] - Net profit attributable to shareholders was ¥64,356,480.65, down 40.86% from ¥108,821,010.06 in the previous year[17] - Basic earnings per share decreased to ¥0.40, a decline of 41.18% from ¥0.68 in 2022[17] - Operating cash flow net amount was ¥53,290,425.47, representing a 57.85% decrease from ¥126,429,397.43 in 2022[17] - Total assets at the end of 2023 were ¥930,405,790.36, down 2.86% from ¥957,759,191.66 at the end of 2022[17] - The company reported a weighted average return on equity of 7.62%, down from 12.88% in the previous year[17] - The net profit after deducting non-recurring gains and losses was ¥60,123,577.68, a decrease of 42.72% from ¥104,960,678.02 in 2022[17] - The company experienced a decline in quarterly revenue, with the fourth quarter revenue at ¥54,285,904.08, down from previous quarters[19] Dividend Distribution - The company plans to distribute a cash dividend of ¥4.00 per 10 shares, totaling approximately ¥64,000,000 based on 160,000,000 shares[3] - The company plans to distribute at least 20% of its distributable profits as cash dividends, with a minimum of 15% if there are no major capital expenditures[130][129] - The company will maintain a consistent and stable profit distribution policy, ensuring that cash dividends are prioritized when conditions are met[132][131] - The company's cash dividend policy remains unchanged during the reporting period, ensuring compliance with relevant regulations and shareholder interests[134] - The available distributable profit for the year is RMB 404,909,630.62, indicating a healthy profit margin for potential distributions[134] Market and Industry Outlook - The company’s industry is positioned within the pharmaceutical manufacturing sector, which is crucial for national health and economic stability, with a growing demand driven by an aging population[27] - As of December 2023, the elderly population (60 years and above) in China reached 297 million, accounting for 21.1% of the total population, which is expected to drive pharmaceutical consumption[27] - The pharmaceutical industry is experiencing stable growth driven by factors such as rising income levels, increased medical insurance coverage, and an aging population, providing favorable conditions for the company's business development[33] - The company faces both opportunities and challenges due to the ongoing reforms in the pharmaceutical industry, which may lead to increased competition and market consolidation[29] Product Development and R&D - The company operates in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine and modern healthcare products, with a product range that includes cardiovascular, orthopedic, respiratory, digestive, and urological systems[30] - Key products include Huangqi Shengmai Drink, Shenjindan Capsules, and Western Ginseng Oral Liquid, with Huangqi Shengmai Drink targeting coronary heart disease and Shenjindan Capsules addressing various orthopedic conditions[31] - The company has developed a sugar-free version of Huangqi Shengmai Drink and a unique product Huangqi Shengmai Granules to cater to the growing demand from patients sensitive to sugar[34] - Research and development expenses totaled CNY 1,513.42 million, representing 5.60% of total revenue, focusing on new product innovation and process optimization[40] - The company completed the secondary development of its product, Zengye Granules, and initiated prospective studies on its unique product, Shanshiguben Granules, in collaboration with several hospitals[41] - The company has established a provincial-level high-tech research and development center and collaborates with several universities for product innovation, holding 11 core independent intellectual property rights[34] Risk Management - The company is actively monitoring potential risks and aims to achieve its operational goals for 2024[3] - The company faces risks from industry policy changes, including stricter regulations and potential impacts on sales and pricing due to healthcare reforms[85] - The company is addressing the risk of product concentration, as three main products significantly influence revenue and profitability[85] - The company is actively working to mitigate risks associated with raw material price fluctuations, which could adversely affect profitability[86] Governance and Management - The board of directors consists of 9 members, including 3 independent directors, and held 5 meetings during the reporting period, reviewing 17 proposals[92] - The supervisory board, comprising 3 members, held 5 meetings and reviewed 15 proposals, ensuring compliance and effective supervision of management[92] - The company emphasizes transparency in information disclosure, adhering to legal regulations and ensuring equal access to information for all shareholders[94] - The company has established a complete and independent financial management system, with dedicated accounting personnel and independent decision-making capabilities[98] - The company has a strong management team with extensive experience in the pharmaceutical industry, including key figures with backgrounds in quality control and procurement[104] Environmental Responsibility - The company has implemented a wastewater treatment station that adheres to the national "Comprehensive Wastewater Discharge Standards" level three (GB8978-1996) with actual discharge concentrations of COD and ammonia nitrogen within the approved limits[147] - The company donated 1 million yuan to the Shenzhou Charity Association to support education, healthcare, and assistance for the underprivileged during the reporting period[150] - The company has passed clean production audits and ISO14001 environmental management system certification, ensuring effective environmental management practices[147] - The company emphasizes environmental protection and has implemented measures to reduce carbon emissions, including online monitoring of wastewater discharge[146] Future Plans - The company aims for a revenue growth target of 0-10% for 2024 compared to the previous year[84] - The company plans to strengthen its marketing network and expand into provincial markets, focusing on both domestic and new market growth[82] - The company is accelerating the construction of its "Modern Traditional Chinese Medicine R&D Center" to foster new product development and technology application[83] - The company is committed to enhancing its internal audit processes with a detailed plan for 2024, showcasing a focus on governance and risk management[121]

目 录 | 一、审计报告……………………………………………………… | 第 | 1—5 | | 页 | | --- | --- | --- | --- | --- | | 二、财务报表……………………………………………………… 第 6—13 | | | | 页 | | （一）合并资产负债表…………………………………………… 第 | | | 6 | 页 | | （二）母公司资产负债表………………………………………… 第 | | | 7 | 页 | | （三）合并利润表………………………………………………… 第 | | | 8 | 页 | | （四）母公司利润表……………………………………………… 第 | | | 9 | 页 | | （五）合并现金流量表……………………………………………第 10 | | | | 页 | | （六）母公司现金流量表…………………………………………第 11 | | | | 页 | | （七）合并所有者权益变动表……………………………………第 12 | | | | 页 | | （八）母公司所有者权益变动表…………………………………第 13 | | | | 页 | 三、财务报表附注……… ...

浙江新光药业股份有限公司 关于召开公司 2023 年度股东大会通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"）第四届董事会第十三次会 议审议通过了《关于提请召开公司 2023 年度股东大会的议案》，决定于 2024 年 5 月 17 日召开公司 2023 年度股东大会，审议董事会、监事会提交的相关议案。 现将本次股东大会的有关事项通知如下： 证券代码：300519 证券简称：新光药业 公告编号：2023-010 一、召开会议的基本情况 1、股东大会届次：2023 年度股东大会。 2、股东大会召集人：公司董事会。公司第四届董事会第十三次会议决定于 2024 年 5 月 17 日召开 2023 年度股东大会。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件、深交所业务规则和《公司章程》等规定。 4、会议召开的日期、时间 （1）现场会议召开时间：2024 年 5 月 17 日（星期五）下午 14:00； （2）网络投票时间：2024 年 5 月 17 日，其中： ...

证券代码：300519 证券简称：新光药业 公告编号：2024-005 浙江新光药业股份有限公司 第四届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席孙筑平召集，会议通知于 2024 年 4 月 7 日以 电子邮件、电话等形式送达全体监事，监事会会议通知中包括会议的相关材料， 同时列明了会议的召开时间、地点、内容和方式。 2、本次监事会于 2024 年 4 月 18 日在公司会议室召开，采取现场投票的 方式进行表决。 3、本次监事会应到 3 人，实际出席会议人数为 3 人。 4、本次监事会由监事会主席孙筑平先生主持，公司董事会秘书、财务总 监和证券事务代表列席了本次监事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等 法律法规和《公司章程》的有关规定。 二、监事会会议审议情况 会议审议并通过了如下议案： 1、审议通过《2023 年度监事会工作报告》 具体内容详见公司公布在中国证监会指定创业板信息披露网站的《2023 年 度监事会工作报告》。 表决结果：赞成 3 ...

2023 年度募集资金存放与使用情况的核查意见 太平洋证券股份有限公司（以下简称"太平洋证券"或"保荐机构"）作为浙江 新光药业股份有限公司（以下简称"新光药业"或"公司"）首次公开发行股票并在 创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等相关法律法规和监管部门的要求，对公司 2023 年 度募集资金存放与使用情况进行了核查，发表如下核查意见： 太平洋证券股份有限公司 关于浙江新光药业股份有限公司 一、募集资金基本情况 （一）公开发行股票募集资金基本情况 经中国证券监督管理委员会《关于核准浙江新光药业股份有限公司首次公开 发行股票的批复》（证监许可[2016]1179 号）核准，并经深圳证券交易所同意向 社会公开发行人民币普通股（A 股）股票 2,000 万股，每股面值 1 元，发行价格 为每股人民币 12.20 元，募集资金总额为 24,400.00 万元，扣除发行费用总额人 民币 3,233.00 万元后，公司募集资金净额为人民币 21,167.00 万元，天健会计师 事务所（ ...

证券代码：300519 证券简称：新光药业 公告编号：2024-006 浙江新光药业股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日召开 第四届董事会第十三次会议、第四届监事会第十三次会议，审议通过了《关于公 司 2023 年度利润分配预案的议案》，该议案尚需提交公司 2023 年度股东大会审 议。现将具体情况公告如下： 公司 2023 年度利润分配预案符合《公司法》、《证券法》、《企业会计准 则》、《关于进一步落实上市公司现金分红有关事项的通知》、《上市公司监管 指引第 3 号——上市公司现金分红》及《公司章程》等规定。符合公司确定的利 润分配政策和分红回报规划，有利于全体股东共享公司经营成果，具备合法性、 合规性、合理性。 一、利润分配预案基本情况： 经天健会计师事务所（特殊普通合伙）审计，公司 2023 年度实现归属于上 市公司股东的总净利润为 64,356,480.65 元（其中母公司净利润 64,247,849.76 元 ...